Updated Nov. 6, 2011 at 9:09 a.m.

Premium Lock Pozen CEO criticizes partner AstraZeneca for slow drug sales

Published: 2011-11-06 09:01:00
Updated: 2011-11-06 09:09:01

Pozen Image 1 of 2 · Next Image…

"Although last quarter's U.S. net sales were up from the second quarter, the $13.4 million year to date total is well below what we think Vimovo is capable of selling so AstraZeneca has work to be done to make that better," John Platchetka says....

Read More
Read More

Copyright 2014 MedCity. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Scroll